- Alternative PROTAC Technology Development
- Biomolecule-Conjugated PROTAC Technology Development
- Hydrophobic Tagging Technology Development
- Molecular Glue Technology Development
- PROTAC Degradation Technology Development
- SNIPER Technology Development
Ubiquitin-Proteasome Based Degradation Technology Development
The ubiquitin-proteasome system (UPS) has become a central engine for modern targeted protein degradation, enabling researchers to move beyond occupancy-driven inhibition toward selective removal of disease-relevant proteins. At BOC Sciences, we provide integrated UPS-based degradation technology development services for pharmaceutical companies, biotechnology innovators, academic teams, and discovery partners seeking practical solutions for difficult targets, degrader mechanism studies, and candidate optimization.
Our capabilities span target feasibility assessment, degrader concept selection, E3 ligase strategy design, molecular design and synthesis, ubiquitination and degradation assay development, ternary complex evaluation, and downstream developability studies. Whether your project focuses on bifunctional degraders, molecular glue technology development, or mechanism-driven UPS biology exploration, we build tailored workflows that align with your target class, research hypothesis, and data package expectations.
Services
Comprehensive UPS-Based Degradation Technology Development Services
Target Assessment and Degradability Analysis
Successful UPS-based degradation programs begin with understanding whether the protein of interest is biologically relevant, chemically addressable, and mechanistically suitable for proteasomal removal. We assess target localization, protein turnover, expression context, tractable binding pockets, degron accessibility, and known resistance liabilities to define a realistic development path.
- Target biology and mechanism review
- Degradability hypothesis generation
- Subcellular localization and pathway assessment
- Entry-strategy comparison for PROTAC, molecular glue, and ligase-driven approaches
Rational Degrader Design Strategy
We translate target and ligase biology into actionable degrader design concepts. For bifunctional programs, our scientists integrate warhead quality, ligase compatibility, linker geometry, and ternary complex requirements to prioritize synthetically realistic molecules with a higher probability of productive ubiquitination.
- PROTAC design services for target-specific degrader ideation
- Ligand design for E3 ligase selection and matching
- Linker design and optimization services
- Conjugation site and topology assessment
E3 Ligase Strategy Development
E3 choice often determines degradation efficiency, selectivity, tissue relevance, and translational tractability. We help clients compare established and emerging ligase options, evaluate target-ligase compatibility, and define the most appropriate UPS recruitment strategy for each project stage.
- CRBN, VHL, IAP, and MDM2 strategy comparison
- Tissue and cell-context ligase suitability analysis
- VHL-based PROTAC development support
- CRBN-based PROTAC development support
Ubiquitination and Mechanism Validation
For many clients, the key question is not only whether protein levels decline, but whether the mechanism is truly UPS-mediated. We establish fit-for-purpose workflows to connect target engagement, ligase recruitment, ubiquitin transfer, and proteasomal degradation into one interpretable data package.
- Protein ubiquitination services
- E3 ubiquitin ligase activity assay
- TR-FRET in-vitro ubiquitylation assay
- Proteasome dependency confirmation and rescue experiment design
Degradation Activity Evaluation
We build decision-ready degradation datasets by combining biochemical and cellular readouts. Our evaluation framework is designed to answer the questions most relevant to discovery teams: Does the molecule degrade? How strongly? How selectively? Under what exposure window? And which structural features drive the best performance?
- PROTAC ternary complex assay
- Degradation ability assay
- Dose-response and time-course degradation profiling
- Cell-based validation across relevant disease models
Developability and Advancement Support
UPS-based degraders often succeed or fail on multiparameter balance rather than potency alone. We therefore integrate chemistry and biology with developability thinking, helping clients improve permeability, solubility, metabolic stability, and exposure while preserving degradation performance.
- Structure-property-degradation relationship analysis
- Liability identification and design iteration
- Candidate prioritization for follow-up studies
- PROTAC in vivo evaluation planning and execution
Are These the Bottlenecks Slowing Your UPS-Based Degradation Program?
- Unclear whether the target is truly degradable through the ubiquitin-proteasome system
- Difficulty choosing between PROTAC, molecular glue, or other UPS-oriented approaches
- Limited confidence in E3 ligase selection and target-ligase compatibility
- Poor ternary complex productivity despite acceptable binary binding
- Weak cellular degradation caused by permeability, efflux, or hook-effect liabilities
- Insufficient mechanistic evidence linking ubiquitination to observed target loss
Tell Us Your Challenge
Share your target, degrader modality, or assay question, and our team will help define a practical development strategy.
Submit InquiryChallenge Solving
How We Solve Critical Challenges in UPS-Based Degradation Technology Development?
Our workflows are designed around the real questions discovery teams ask at each stage of a degradation project, from mechanism feasibility to candidate advancement.
Clarifying Whether a Target Is Suitable for UPS-Mediated Degradation
We combine literature mining, pathway logic, ligand accessibility analysis, protein biology review, and experimental planning to determine whether a project should proceed with a degrader strategy and which modality is most appropriate. This reduces early-stage risk and helps teams avoid spending chemistry effort on low-probability concepts.
Improving the Odds of Productive Ubiquitination
Productive degradation depends on more than target binding. We optimize warhead attachment points, ligase pairing, linker length, linker composition, and ternary geometry so that target engagement can translate into efficient ubiquitin transfer and proteasome recognition.
Distinguishing Real Mechanism from Apparent Target Reduction
Protein loss in cells can arise from multiple causes. We design orthogonal experiments to verify ligase dependence, ubiquitination status, proteasome involvement, and structure-mechanism consistency, giving clients more confidence in hit triage, SAR decisions, and program direction.
Balancing Degradation Performance with Molecular Properties
Many UPS degraders face challenges in permeability, solubility, metabolic stability, and dose-response behavior. We apply multiparameter optimization to improve overall molecule quality rather than chasing one isolated metric, helping clients advance candidates that are both mechanistically strong and experimentally workable.
Turn UPS Biology into a Practical Degrader Development Strategy
BOC Sciences helps clients convert mechanistic insight into workable degrader programs by integrating target assessment, design logic, assay development, and optimization under one coordinated workflow.
Technology Scope
UPS-Based Degradation Modalities We Support
Classical and Extended Bifunctional Degraders
We support a broad range of bifunctional degrader strategies for clients seeking to translate target-binding ligands into productive UPS-mediated degradation programs. In addition to standard PROTAC degradation technology development, we also provide support for covalent PROTAC technology, HaloPROTAC technology, and peptide-based PROTAC technology, depending on target biology, ligand properties, and project objectives.
Molecular Glue Degraders
For programs that do not require a bifunctional architecture, we support molecular glue-based discovery and validation strategies aimed at promoting productive target-ligase interactions through a more compact and mechanism-driven design concept. This route is particularly valuable when linker dependence becomes a major limitation or when clients want to explore alternative UPS entry points.
Self-Dimerizing and Alternative PROTAC Formats
We also work with non-classical degrader formats designed to expand mechanistic flexibility and target coverage. These include Homo-PROTAC technology development for ligase self-dimerization-driven degradation concepts, as well as alternative PROTAC technology development for clients evaluating less conventional degrader architectures and next-generation design hypotheses.
Macromolecule-Guided Degradation Concepts
For targets that may benefit from expanded recognition elements or nucleic acid-enabled targeting logic, we support emerging macromolecule-oriented approaches such as oligonucleotide-base PROTAC technology development. These strategies can be useful when traditional small-molecule degrader design faces limitations in target engagement, selectivity, or biological context.
Workflow
End-to-End Workflow for UPS-Based Degradation Technology Development
01
Project Definition and Target Review
We collect target background, available ligands, desired modality, disease rationale, decision criteria, and experimental constraints.
02
Feasibility and Modality Selection
Our team evaluates whether PROTAC, molecular glue, or an assay-first UPS strategy is the most suitable route for the project.
03
E3 Ligase and Design Framework Definition
We define ligase options, design logic, attachment strategies, and the assay package needed to validate productive ubiquitination and degradation.
04
Molecule Design and Experimental Planning
We prioritize design hypotheses, synthesis routes, controls, and readouts to generate interpretable structure-mechanism data.
05
Synthesis and Assay Execution
Candidate molecules are prepared and evaluated through biochemical, cellular, and mechanistic assays aligned with project goals.
06
Mechanism Confirmation and Hit Triage
We connect target engagement, ligase activity, ubiquitination behavior, ternary complex formation, and degradation output to identify the most credible leads.
07
Optimization and Developability Assessment
We refine chemistry and evaluate key molecular liabilities to improve overall candidate quality and experimental robustness.
08
Data Delivery and Next-Step Recommendations
Clients receive organized data interpretation, prioritized candidates, and practical guidance for follow-up validation or expansion studies.
Advantages
Advantages of UPS-Based Degradation Technology
Removes the Target Protein Itself
Unlike conventional inhibitors that mainly block one functional site, UPS-based degradation technology eliminates the target protein itself and can produce broader biological effects in suitable systems.
Expands Access to Challenging Targets
UPS-based strategies provide a practical route for targets that are difficult to modulate effectively through traditional small-molecule inhibition, including certain non-enzymatic and scaffolding proteins.
Supports Event-Driven Pharmacology
Because activity depends on triggering a productive degradation event rather than maintaining continuous occupancy alone, this technology offers a distinct pharmacological logic for discovery and optimization.
Offers Multiple Degrader Formats
The ubiquitin-proteasome system supports a range of modalities, including bifunctional degraders, molecular glues, and alternative architectures, giving researchers greater flexibility in target-specific design.
Applications
Research Applications Supported by Our UPS-Based Degradation Services
Oncology Research
- Removal of transcriptional regulators, scaffolding proteins, and resistance-associated targets
- Expansion beyond inhibition for hormone receptor and epigenetic target programs
- Degrader strategy exploration for difficult-to-drug oncogenic proteins
- Mechanism studies for target dependency and degradation response biomarkers
Immunology and Inflammation
- UPS-driven removal of signaling mediators and pathway regulators
- Selective degradation approaches for kinases, adaptors, and scaffold proteins
- Mechanism validation in immune-relevant cell systems
- Support for early-stage degrader concept testing in inflammatory pathways
Neurodegeneration and CNS Biology
- Feasibility analysis for degradation of aggregation-prone or disease-driving proteins
- Assessment of brain-relevant design constraints and exposure-related tradeoffs
- Support for Tau, α-synuclein, and pathway-adjacent target programs
- Comparative evaluation of direct and indirect UPS-based strategies
Platform and Tool Compound Development
- Discovery of degrader tool compounds for pathway dissection
- UPS assay platform construction for internal screening campaigns
- E3 ligase biology exploration and substrate relationship studies
- Generation of mechanism-rich datasets for partner-facing research programs
Case Study
Client Success Stories: Ubiquitin-Proteasome Based Degradation Technology Development
Project Background
A biotech client had a hematologic malignancy target with strong disease relevance but limited success from inhibitor optimization. The team wanted to test whether a UPS-based degrader strategy could produce deeper pathway suppression than occupancy-based inhibition.
Our Support
We began with a degradability and target-accessibility assessment, then designed two bifunctional degrader series around the client's validated binding motif using alternative ligase recruitment logic. Across the first design cycle, we prepared 18 molecules with varied linker composition, attachment vectors, and ligand polarity. Ternary complex profiling and cell-based degradation studies identified one VHL-oriented series with clearly superior productivity. Follow-up optimization narrowed the set to 6 prioritized analogs, of which 2 delivered DC50 values below 100 nM in the client's lead cell model and showed more than 80% target reduction at 6 hours, while negative-control analogs did not reproduce the effect.
Project Outcome
The client obtained a credible UPS-mediated degrader series, a cleaner mechanism package linking ligase recruitment to target loss, and a more focused medicinal chemistry direction for subsequent optimization.
Project Background
A discovery-stage partner was exploring an immunology target for which bifunctional degrader architecture appeared chemically challenging. The client wanted a structured way to evaluate whether a molecular-glue-like UPS approach could be feasible, but lacked an internal workflow for ligase dependency testing, ubiquitination readouts, and orthogonal mechanism confirmation.
Our Support
We designed a staged mechanism-first program combining target biology review, ligase shortlist generation, biochemical interaction studies, ubiquitination readouts, and cellular protein reduction assays. We screened 24 focused compounds and analogs across a tiered cascade that included ligase activity testing, ubiquitination signal tracking, proteasome-dependency confirmation, and target-selective immunoblot analysis. Three compounds showed reproducible target reduction, and one chemotype produced a consistent UPS-linked signature with proteasome rescue, measurable ubiquitination enhancement, and limited impact on related pathway proteins under the same conditions.
Project Outcome
The partner received a practical feasibility conclusion, a prioritized chemotype for expansion, and an assay workflow that could be reused for future UPS-based discovery efforts on the same target family.
Why Choose Us
Why Choose BOC Sciences for Your UPS-Based Degradation Program?
Target-to-Mechanism Coverage
We support the full path from target assessment and degrader concept selection to mechanistic validation and candidate-focused optimization.
Assay Packages Built for Decision-Making
Our readouts are selected to answer the questions that actually drive progression decisions, not just to generate isolated endpoint values.
Customization Around Your Scientific Hypothesis
We tailor each workflow to the target class, modality, available ligands, and maturity of the client's project.
Experience with UPS-Specific Challenges
We address ligase compatibility, hook effect, ternary geometry, ubiquitination efficiency, and property-driven performance loss in a coordinated way.
Natural Integration with Internal Discovery Teams
Our modular support model fits exploratory feasibility studies, assay outsourcing, chemistry expansion, and broader partner-driven discovery workflows.
Clear Reporting and Actionable Next Steps
We provide structured interpretation that helps clients decide whether to expand, redesign, deprioritize, or reposition a degradation strategy.
Frequently Asked Questions (FAQ)
Why is ubiquitin-proteasome degradation technology attracting attention?
Ubiquitin-proteasome degradation technology has gained strong interest in drug discovery because it enables targeted removal of disease-relevant proteins rather than simply inhibiting their activity. This mechanism creates new opportunities for addressing proteins that are difficult to modulate with conventional small molecules, especially when sustained pathway shutdown or broader functional elimination is needed. For discovery teams seeking differentiated strategies, this approach can expand tractable target space and improve mechanism-based design options. BOC Sciences supports such programs through integrated services including target assessment, degrader design, linker optimization, and in vitro evaluation, helping clients move degradation-based projects forward more efficiently.
Which drug discovery projects are best suited for targeted protein degradation?
Targeted protein degradation is especially valuable for projects involving proteins that are poorly addressed by conventional inhibitors, including non-enzymatic proteins, scaffold proteins, transcriptional regulators, and targets where partial inhibition does not deliver sufficient biological impact. It is also attractive when drug developers want to explore novel mechanisms, overcome limits of occupancy-driven pharmacology, or expand pipeline differentiation. In practice, suitability depends on target biology, ligand accessibility, degradation feasibility, and the intended therapeutic strategy. A careful early-stage assessment can help determine whether a degradation approach offers a meaningful advantage over traditional modulation methods.
What are the biggest challenges in degrader development?
One of the biggest challenges in degrader development is that success depends on more than target binding alone. Effective molecules must promote productive ternary complex formation among the target protein, the E3 ligase, and the degrader, while also supporting ubiquitination and downstream proteasomal processing. This requires coordinated optimization of ligand selection, linker length, linker flexibility, spatial orientation, cell permeability, and selectivity. Because these factors interact in complex ways, degrader discovery often demands iterative design and testing. BOC Sciences offers medicinal chemistry and synthesis support for degrader optimization, helping clients address these technical bottlenecks in a structured manner.
How can researchers assess whether a target is degradable?
Assessing whether a target is suitable for degradation generally requires a combination of biological and chemical evaluation. Researchers usually examine whether the protein plays a clear disease-driving role, whether it contains ligandable regions, whether complete protein removal is more beneficial than simple functional inhibition, and whether its cellular context is compatible with ubiquitination and proteasomal turnover. Additional considerations include subcellular localization, protein turnover behavior, and expected downstream biological effects after depletion. BOC Sciences can support early feasibility studies and customized development workflows that help clients evaluate target degradability and reduce uncertainty in project planning.
How does degrader development differ from traditional inhibitor discovery?
Degrader development differs from traditional inhibitor discovery because it is based on an event-driven mechanism rather than continuous target occupancy. Instead of maintaining prolonged inhibition at an active site, a degrader only needs to trigger a productive degradation event that leads to target protein removal and sustained biological consequences. As a result, discovery strategy shifts from optimizing binding affinity alone to balancing ternary complex stability, degradation efficiency, selectivity, and cellular performance. This requires different screening concepts and optimization logic. For drug developers building innovative pipelines, understanding these distinctions is essential for designing an effective protein degradation program.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
